Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio Farma Offers Partnerships in Vaccine Development

Published: Monday, October 29, 2012
Last Updated: Monday, October 29, 2012
Bookmark and Share
Company to partner with vaccine manufacturers in developing and Islamic countries.

Indonesian vaccine-maker Bio Farma President Director Iskandar said the company he leads is ready to partner with vaccine manufacturers in developing and Islamic countries, particularly in the research and development of new vaccines.

"We hope that Bio Farma, as the only vaccine manufacturer in Indonesia, can be a hub or center for research and development of vaccines and serve as a partner to research new vaccines for developing countries," Iskandar told reporters in Bali on Sunday.

Iskandar made the statement as host of the 13th Developing Country Vaccine Manufacturers Networks (DCVMN) to be held in Bali on 31 October to 2 November 2012.

According to Iskandar, all vaccine producers in the world have the same ultimate goal, namely to increase the availability and quality of vaccines in order to achieve healthy communities.

He explained that the purpose of holding the DCVMN meeting is to jointly combat the spread of infectious diseases that are endemic in many developing countries.

This is to be achieved through increasing the capacity and quality of vaccines and improving vaccine research and development.

Iskandar said regular meetings of vaccine manufacturers in developing countries are needed to encourage the production and distribution of high-quality vaccines selectively in the long term to meet the targets of the national immunization program for these countries.

The Bio Farma president director said he had participated in the Global Health Product Development Conference 2012 in Seattle, 1-3 May 2012, where he gave a presentation on the achievements of Indonesia's only vaccine manufacturer, which is today 122 years old.

In the international meeting Iskandar explained Bio Farma has produced 11 types of vaccines and all have world-class recognition, namely the recognition of pre-qualification from the World Health Organization (WHO).

This fact interested partners of the Bill and Melinda Gates Foundation, the originator of the international meeting in Seattle, and many of them expressed interest in working with Bio Farma in conducting clinical trials and the development of vaccines, Iskandar pointed out.

The panelists at the meeting, among others represented, include Subhash Kapre (Serum Institute of India), Yang Xiaoming (China National Biotech Group), Akira Homma (Bio-Manguinhos), and Iskandar (Bio Farma).

The Bill and Melinda Gates Foundation is also scheduled to attend as a participant, represented by Dr. Kim Bush. More than 100 international vaccine researchers and experts have confirmed attendance at the conference.

DCVMN member countries are Argentina, Bangladesh, Brazil, Cuba, Egypt, India, Indonesia, Iran, Mexico, Republic of China, Republic of Korea, South Africa, Thailand and Vietnam.

DCVMN member companies and organizations are Beijing Minhai Biotechnology Bharat Biotech International Limited, Biological E. Limited, Bio-Manguinhos - Institute of Technology on Immunobiologicals, BioNet-Asia Co., Ltd., Cadila Pharmaceuticals Limited, Center for Genetic engineering and Biotechnology Chengda Liaoning, China National Biotec Group (CNBG).

Other members include EuBiologics, Finlay Institute, Haffkine, Hualan Bio, Incepta Ltd., Indian Immunologicals Limited, Institute of Vaccines and Medical Biologicals, Instituto Butantan, National Administration of Laboratories and Institute of Health ANLIS "Dr. Carlos G. Malbran."

Also represented are Panacea Biotec Ltd, Pasteur Institute of Iran, Bio Farma, Queen Saovabha Memorial Institute, Razi Vaccine & Serum Research Institute, Serum Institute of India Ltd, Sinergium, Sinovac Biotech Ltd., SK Chemicals, Biovac Institute, Company for Vaccine and Biological Production No.1 - Vabiotech, Government Pharmaceutical Organization-Holding Company for Biological Products & Vaccines (VACSERA), Tiantan, Walvax and Xiamen Innovax Biotech.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bio Farma Urges OIC Countries to Strengthen Vaccine Cooperation
Bio Farma to make OIC Countries self-reliance in vaccine industry.
Monday, June 17, 2013
Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!